| 193.3 2.42 (1.27%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 231.63  |
1-year : | 244.52 |
| Resists | First : | 198.32 |
Second : | 209.35 |
| Pivot price | 196.97 |
|||
| Supports | First : | 180.47 |
Second : | 150.15 |
| MAs | MA(5) : | 193.91 |
MA(20) : | 197.16 |
| MA(100) : | 181.62  |
MA(250) : | 184.02 |
|
| MACD | MACD : | -0.2 |
Signal : | 1 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 21.8 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 281.82 | Low : | 125.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PODD ] has closed above bottom band by 22.9%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 198.51 - 199.62 | 199.62 - 200.64 |
| Low: | 177.73 - 179.09 | 179.09 - 180.34 |
| Close: | 191.22 - 193.3 | 193.3 - 195.21 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Fri, 26 Jul 2024
Natixis Makes New Investment in Insulet Co. (NASDAQ:PODD) - MarketBeat
Fri, 26 Jul 2024
Insulet preliminary Q2 revenue report beats The Street - Drug Delivery Business News
Fri, 26 Jul 2024
Why Is Omnipod Insulin Device Maker Insulet Stock Jumping Today? - Benzinga
Fri, 26 Jul 2024
Insulet's prelim Q2 revenue tops estimates (NASDAQ:PODD) - Seeking Alpha
Fri, 26 Jul 2024
Insulet (PODD) revenue of $488 million, estimate $460.4 million - StreetInsider.com
Fri, 26 Jul 2024
Sei Investments Co. Raises Holdings in Insulet Co. (NASDAQ:PODD) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 70 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 101.7 (%) |
| Shares Short | 2,870 (K) |
| Shares Short P.Month | 2,990 (K) |
| EPS | 3.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.28 |
| Profit Margin | 13.1 % |
| Operating Margin | 12.8 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 36.1 % |
| Qtrly Rev. Growth | 23.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 25.41 |
| EBITDA (p.s.) | 4.84 |
| Qtrly Earnings Growth | 116 % |
| Operating Cash Flow | 233 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | 57.87 |
| PEG Ratio | 4.3 |
| Price to Book value | 17.12 |
| Price to Sales | 7.6 |
| Price to Cash Flow | 58.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|